Publication:
Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease

Placeholder

Organizational Units

Authors

Ulukaya, Engin
Gül, Özen Öz
Arabul, Mahmut
Gül, Cuma Bülent
Oral, Arzu Yılmaztepe
Aker, Sibel
Dolar, Mahmut Enver

Authors

Atuğ, Özlen
Yılmaz, Yusuf

Advisor

Language

Publisher:

Pergamon-Elsevier Science

Journal Title

Journal ISSN

Volume Title

Abstract

Objectives: Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease. Design and methods: We enrolled subjects with definite nonalcoholic steatohepatitis (NASH, n=40), borderline NASH (n=8), simple fatty liver (n=9) and healthy controls (n=14). Plasma levels of sRAGE were measured by ELISA. Results: Concentrations of sRAGE were significantly lower in patients with definite NASH (1080 +/- 392 pg/mL, P<0.01) and borderline NASH (1050 +/- 278 pg/mL, P<0.05) compared to controls (1480 +/- 387 pg/mL). Levels of sRAGE were significantly and inversely correlated with ALT (r=-0.30, P<0.05) and AST (r=-0.23, P<0.05). Conclusion: Plasma levels of sRAGE are significantly reduced in definite and borderline NASH.

Description

Source:

Keywords:

Keywords

Fatty liver, Biological markers, Receptor for advanced glycation endproducts (RAGE), Enzyme-linked immunosorbent assay, End-products ages, Insulin-resistance, Serum-levels, Rage, Form, Pathogenesis, Galectin-3, Protein, Medical laboratory technology

Citation

Yılmaz, Y. vd. (2009). "Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease". Clinical Biochemistry, 42(9), 802-807.

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads